Please login to the form below

Ansar Jawair discusses precision medicines - what they are, where we are today and their future

Ansar Jawair, Founder and CEO of Precision Medicines Ltd, tells us about his talk on precision medicines, what they are, where we are today, the future and some of the challenges involved in their implementation to patients. Precision medicines are matched to patients using biomarkers, enabling to target the specific drivers of various cancers. Major advances have already been made in this field, treating a range of cancers. Some of the major challenges include working with the complexities in different countries, trying to establish diagnostic testing, for enabling precision medicine. He mentions how we are moving towards an era of delivering personalised treatments that are matched to the individual patient. Furthermore, through advances in precision medicines and in diagnostic testing, we are seeing earlier detection of disease and identification of risk factors, allowing for preventative measures.

17th November 2016



Company Details

Brandcast Health

+44 (0)20 7291 5070

Contact Website

16-17 Little Portland Street

Latest content on this profile

Day 2 Round-up from the Giant Health Event
Robin gives a quick overview of day 2 of the Giant Health Event.
Brandcast Health
Why patient education is important in oncology
We talked to Dr Bettina Ryll of Melanoma Patient Network Europe about changes in melanoma treatment and how the added complexity of new treatments has changed how patients need to be informed.
Brandcast Health
CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?
In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients.
Brandcast Health
No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer
The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study with women with relapsed platinum-sensitive high-grade ovarian cancer.
Brandcast Health
FALCON trial of fulvestrant for advanced breast cancer
The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer.
Brandcast Health
Overview of the GIANT Health Event
Shafi Ahmed, PhD, FRCS, Director of Virtual Medics and Medical and GIANT Event Co-chair, provides an overview of the GIANT Health Event.
Brandcast Health